Hypertrophic cardiomyopathy (HC) patients are less active than the general U.S. population. More data are needed on exercise in HC to strike a balance between acute risks and long-term health benefits of exercise.
Published in Brief:
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan